Expert Insights

Jane Meisel, MD, discusses the impact novel antibody drug conjugates have had in the treatment of patients with metastatic breast cancer.

Suresh Ramalingam, MD, discussed results from the phase 3 LAURA study which demonstrated that administration of osimertinib following definitive chemoradiation improved PFS among patients with unresectable, stage 3, EGFR-mutated NSCLC.

Areej El-Jawahri MD, discusses trial results that showed palliative care significantly improved the rates of discussion and documentation of end-of-life care preferences, reduced hospitalization, and improved quality of life for patients with...

Daniel Petrylak, MD, discussed results from a phase 1/2 study that demonstrated that ARV-766 was well tolerated and showed promising clinical activity among patients with androgen receptor LBD-mutated metastatic castration-resistant prostate...

Natasha Leighl, MD, discussed results from the phase 3 PALOMA-3 trial which compared subcutaneous and intravenous amivantamab plus lazertinib in patients with advanced, EGFR-mutated non-small cell lung cancer.

Marina Kremyanskaya, MD, PhD, shares study results from the REVIVE trial in which rusfertide demonstrated improved hematocrit control and decreased the use of phlebotomy among patients with polycythemia vera.

At Great Debates and Updates in Gastrointestinal Malignancies in New York, New York, Michael Overman, MD, discussed advantages associated with treating patients with MSI-high colorectal cancer with doublet immunotherapy.

At Great Debates and Updates in Gastrointestinal Malignancies in New York, New York, Michael Lidsky, MD, discussed ways researchers are working to overcome barriers to hepatic arterial infusion pump therapy limitations for patients with...

At Great Debates and Updates in Gastrointestinal Malignancies in New York, New York, Michael Hall, MD, MS, discussed limitations to performing germline genetic testing on all patients with gastrointestinal cancers.